Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma.
Paraprotein induced renal failure is a frequent complication of multiple myeloma and is associated with poor survival. Previously, reversal of renal function has been hampered by the lack of fast acting and highly effective myeloma therapy and most patients remained or became dependent on hemodialysis. Here we show reversal of acute paraprotein-induced renal failure by bortezomib-based therapy in 5 out of 8 patients. Improvement of renal function was preceded by a significant reduction in paraprotein concentration in all patients, with improvement in renal function.
Ludwig
Heinz
H
Department of Medicine I, Center for Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1170 Vienna, Austria. heinz.ludwig@wienkav.at
Drach
Johannes
J
Graf
Helmut
H
Lang
Alois
A
Meran
Johannes Gobertus
JG
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000368:Aged; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use*
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib